By Ed Silverman April 1, 2019 Reprints Alex Brandon/AP [email protected] GET STARTED Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. In a notable development, the Federal Trade Commission reversed a ruling by an administrative law judge who last year maintained that a so-called pay-to-delay deal between Impax Laboratories and Endo Pharmaceuticals (ENDP) was not anticompetitive.In doing so, the agency is not only reinforcing a 2012 U.S. Supreme Court ruling that found these agreements could be scrutinized for antitrust violations, but it is also buttressing a litmus test for determining when a pay-to-delay deal may be problematic (here is the decision). FTC rules that a pay-to-delay deal was meant to thwart competition Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED Log In | Learn More Tags drug pricinglegalpharmaceuticalsSTAT+ @Pharmalot What is it? Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. About the Author Reprints Ed Silverman What’s included?